Lotus Pharmaceutical Announces Share Purchases by Chairman Robert Wessman, Reflecting Confidence in Company’s Growth Opportunities

Lotus Pharmaceutical Announces Share Purchases by Chairman Robert Wessman, Reflecting Confidence in Company’s Growth Opportunities

Taipei, Taiwan, 16 November 2026 — Lotus Pharmaceutical (1795; “Lotus” or “the Company”), a global pharmaceutical company, today announced that its Chairman, Robert Wessman, has purchased 58,075 shares in the Company through his personal account, using his own funds. The investment reflects his confidence in the Company's long-term growth prospects.

The purchases were completed on 16 November at an average price of approximately NT$140.5 per share, representing a total investment of approximately NT$8.2 million.

Robert Wessman, Chairman of Lotus, commented: “Lotus has built a strong global pharmaceutical platform, with integrated R&D, manufacturing and commercial capabilities. We are now entering an exciting phase, with near-term product launches addressing a combined market opportunity of approximately US$3 billion. My personal investment reflects my strong confidence in our pipeline, our team’s ability to execute and our potential to deliver long-term shareholder value.”

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.

Media Inquiries

Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications

+886 2 2700 5908

investor@lotuspharm.com